[go: up one dir, main page]

HRP20130782T1 - Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin - Google Patents

Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin

Info

Publication number
HRP20130782T1
HRP20130782T1 HRP20130782TT HRP20130782T HRP20130782T1 HR P20130782 T1 HRP20130782 T1 HR P20130782T1 HR P20130782T T HRP20130782T T HR P20130782TT HR P20130782 T HRP20130782 T HR P20130782T HR P20130782 T1 HRP20130782 T1 HR P20130782T1
Authority
HR
Croatia
Prior art keywords
integrin
beta
alpha
compositions
treating
Prior art date
Application number
HRP20130782TT
Other languages
English (en)
Inventor
Dean Sheppard
Amha Atakilit
Original Assignee
The Regents Of The University Of California, Office Of Technology Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Office Of Technology Transfer filed Critical The Regents Of The University Of California, Office Of Technology Transfer
Publication of HRP20130782T1 publication Critical patent/HRP20130782T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20130782TT 2004-04-02 2005-03-30 Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin HRP20130782T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55917504P 2004-04-02 2004-04-02
PCT/US2005/011222 WO2005094391A2 (en) 2004-04-02 2005-03-30 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN

Publications (1)

Publication Number Publication Date
HRP20130782T1 true HRP20130782T1 (en) 2013-09-30

Family

ID=35064346

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130782TT HRP20130782T1 (en) 2004-04-02 2005-03-30 Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin

Country Status (14)

Country Link
US (2) US20050226865A1 (hr)
EP (2) EP1734996B1 (hr)
JP (2) JP5223072B2 (hr)
CN (1) CN1964740A (hr)
AU (1) AU2005229015C1 (hr)
CA (1) CA2562038C (hr)
CY (1) CY1114497T1 (hr)
DK (1) DK1734996T3 (hr)
ES (2) ES2411965T3 (hr)
HR (1) HRP20130782T1 (hr)
PL (1) PL1734996T3 (hr)
PT (1) PT1734996E (hr)
RS (1) RS52918B (hr)
WO (1) WO2005094391A2 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5755647B2 (ja) * 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
US9487780B2 (en) * 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2014144616A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 5 antibodies and uses thereof
EP2970475A1 (en) * 2013-03-15 2016-01-20 Biogen MA Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2015009948A1 (en) * 2013-07-19 2015-01-22 Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
CN107001469A (zh) * 2014-09-12 2017-08-01 比奥根Ma公司 人源化抗‑αvβ5抗体及其用途
WO2019089544A1 (en) * 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US139398A (en) * 1873-05-27 Improvement in lamp-extinguishers
US18192A (en) * 1857-09-15 And samuel m
US37889A (en) * 1863-03-10 Mode of
US19035A (en) * 1858-01-05 mallary
US171271A (en) * 1875-12-21 Improvement in bob-sleds
US77321A (en) * 1868-04-28 Amos bank
US72500A (en) * 1867-12-24 Improvement in bleaceisg and scouring hemp, flax, aid other fibres
US19206A (en) * 1858-01-26 Hydrant
US181440A (en) * 1876-08-22 Improvement in steam-boiler furnaces
US10023A (en) * 1853-09-20 Machine fob sawing sticks eob broom-handles
US19037A (en) * 1858-01-05 Washing-machine
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5231114A (en) 1990-06-22 1993-07-27 Wakunaga Seiyaku Kabushiki Kaisha Polysulfides compounds and lipid peroxidation inhibitor containing the polysulfide compounds as active ingredient
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) * 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
CA2131389A1 (en) 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
RU2214268C2 (ru) * 1995-08-14 2003-10-20 Дзе Скриппс Рисерч Инститьют СПОСОБЫ И КОМПОЗИЦИИ, ПОЛЕЗНЫЕ ДЛЯ ПОДАВЛЕНИЯ АНГИОГЕНЕЗА, ОПОСРЕДОВАННОГО αvβ5
EA001779B1 (ru) 1996-05-01 2001-08-27 Эли Лилли Энд Компани Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия
KR100595740B1 (ko) 1996-08-12 2006-07-03 미쯔비시 웰 파마 가부시키가이샤 Ｒｈｏ 키나아제 억제제를 함유하는　약제
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
PT1930022E (pt) * 1997-08-08 2011-08-01 Univ California Tratamento da fibrose vesical com anticorpos contra integrina alfa-v-beta 6
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
JP2002533419A (ja) 1998-12-30 2002-10-08 イーデマ クリアランス， インコーポレイテッド Ｎａ，Ｋ−ＡＴＰａｓｅをコードするアデノウイルスベクターを使用する、肺水腫のための遺伝子治療
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399581B1 (en) 1999-05-11 2002-06-04 Harbor Branch Oceanographic Institution, Inc. Compound possessing potent thrombin receptor antagonist activity
CZ20011872A3 (cs) 1999-09-29 2002-03-13 Ortho-Mcneil Pharmaceutical, Inc. Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6544982B1 (en) 1999-10-29 2003-04-08 Merck & Co., Inc. Thrombin receptor antagonists
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP4787447B2 (ja) 2000-01-20 2011-10-05 メルク・シャープ・エンド・ドーム・コーポレイション αｖインテグリン受容体拮抗薬
AU780988B2 (en) 2000-01-24 2005-04-28 Merck & Co., Inc. Alpha V integrin receptor antagonists
US6515023B2 (en) 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
HUP0300544A3 (en) 2000-02-03 2005-03-29 Eisai Co Ltd Pharmaceutical compositions containing integrin expression inhibitors
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
JP2001320372A (ja) 2000-03-13 2001-11-16 Hyundai Electronics Ind Co Ltd 統合インターネットプロトコル網で統合加入者サーバの機能的モデリングを通した統合加入者管理装置及びその方法
WO2001078790A2 (en) 2000-04-18 2001-10-25 Edema Clearance, Inc. GENE THERAPHY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING A β2ADRENERGIC RECEPTOR GENE
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
EP1331937B1 (en) 2000-10-24 2006-03-15 Merck & Co., Inc. Dibenzoxazepine alpha v integrin receptor antagonist
WO2002059300A2 (en) 2000-12-28 2002-08-01 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
CA2443378A1 (en) 2001-04-04 2002-10-17 Allergan, Inc. Methods of screening and using inhibitors of angiogenesis
JP2004529918A (ja) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
JP4554364B2 (ja) * 2002-08-16 2010-09-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物
WO2004106325A1 (en) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Also Published As

Publication number Publication date
CY1114497T1 (el) 2016-10-05
JP5223072B2 (ja) 2013-06-26
CA2562038C (en) 2017-04-25
HK1098077A1 (en) 2007-07-13
ES2671522T3 (es) 2018-06-06
EP2394662A3 (en) 2012-02-22
WO2005094391A2 (en) 2005-10-13
RS52918B (en) 2014-02-28
EP1734996A4 (en) 2008-09-10
AU2005229015A1 (en) 2005-10-13
CN1964740A (zh) 2007-05-16
PL1734996T3 (pl) 2013-09-30
JP5681149B2 (ja) 2015-03-04
JP2007531733A (ja) 2007-11-08
EP1734996A2 (en) 2006-12-27
DK1734996T3 (da) 2013-06-10
AU2005229015B2 (en) 2012-08-30
PT1734996E (pt) 2013-07-18
JP2013028611A (ja) 2013-02-07
CA2562038A1 (en) 2005-10-13
AU2005229015C1 (en) 2013-01-17
US20050226865A1 (en) 2005-10-13
US20090280118A1 (en) 2009-11-12
EP2394662A2 (en) 2011-12-14
US7815908B2 (en) 2010-10-19
WO2005094391A3 (en) 2005-12-01
EP2394662B1 (en) 2018-03-21
ES2411965T3 (es) 2013-07-09
EP1734996B1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
PL1771201T3 (pl) Kompozycje i sposoby leczenia lub profilaktyki choroby związanej ze szczawianem
EP1965816A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
PL1908779T3 (pl) Pochodne tymozyny beta 4 i ich zastosowanie
LT1920065T (lt) Anti-alfa v beta 6 antikūnai ir jų panaudojimas
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
TWI348891B (en) Composition for preventing plant diseases and method for preventing the diseases
EP1944277A4 (en) ANTI-ARTICLE AND ANTIBACITY COMPOSITION
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP1589996A4 (en) ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES
EP1668024A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING
IL187620A0 (en) 17??-hsd1 and sts inhibitors
ZA200707407B (en) Composition for preventing plant diseases and method for preventing the diseases
SI1921077T1 (sl) Sredstvo za zdravljenje in/ali preprečevanje motnje spanja
EP1814575A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISORDERS
EP1512415A4 (en) LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES
AU2003212850A8 (en) Methods and compositions for treating cardiovascular disease
IL178598A0 (en) Skin-protecting alkalinity-controlling composition and the use thereof
EP1583966A4 (en) METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING GENES 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33
PL1762219T3 (pl) Fotoochronne i/lub fotoimmunoochronne kompozycje do skóry i ich zastosowania
HRP20130782T1 (en) Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
SI1734996T1 (sl) Postopki in sestavki za zdravljenje in preprečevanje bolezni, povezane z integrinom alfa v beta 5
EP1850827A4 (en) COMPOSITION FOR TREATING AND PREVENTING PERIODONTAL DISEASE AND USE METHOD
EP1807067A4 (en) SPHINGOSINKINASE ACTIVATOR AND TREATMENT AGENT FOR SKIN DISEASES THEREWITH
EP1660114A4 (en) METHOD AND COMPOSITIONS FOR TREATING DYSFUNCTIONS OF THE EXTRACELLULAR MATRIX
EP1829860A4 (en) 9,10-SECOPREGNANDERIVAT AND MEDICINE